January 2026 - Stablepharma

Stablepharma and AFT Pharmaceuticals partner to address multi-billion dollar anti-infective and oncology market

Posted on 21 Jan 2026

London, UK – 15 January 2026 – Stablepharma Limited, specialists in thermostable formulations, today announced a development and option-to-license agreement with AFT Pharmaceuticals to develop a portfolio of fridge-free sterile injectable medicines, initially targeting anti-infective and oncology treatments in a total global market valued at over USD 6 billion. Stablepharma will apply its proprietary stabilisation […]

Stablepharma Announces Database Lock for Fridge-Free Tetanus-Diphtheria Vaccine Clinical Trial

Posted on

London, UK – 03 November 2025 – Stablepharma announced the database lock of its Phase 1 clinical trial of the world’s first, fridge-free, tetanus-diphtheria vaccine, SPVX02, which began recruitment in April this year. The trial evaluated the safety, tolerability and immunogenicity of SPVX02 against 2 comparator vaccines and enrolled 60 healthy participants at 2 UK […]